After another day full of presentations on the latest in HIV science at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI)Exit Disclaimer in Seattle yesterday, February 25, we had the opportunity to speak again with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). He shared his thoughts on two highlights from the day’s many presentations.

Dr. Dieffenbach’s first highlight was a featured presentation by Ambassador Deborah Birx, MDExit Disclaimer, who is Coordinator of the U.S. Government Activities to Combat HIV/AIDS and U.S. Special Representative for Global Health Diplomacy. Ambassador Birx spoke about what she calls PEPFAR 3.0 about a new class of drugs that actually can activate latent virus and eliminate it in ways we haven’t seen before. In light of those findings a drug company will soon begin a human clinical trial it was announced at the conference.Tomorrow Dr. Dieffenbach will share brief highlights of the science presented on the conference’s final day.